<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Dec. 5, 2018 (HealthDay News) — Skin autofluorescence predicts incident type 2 diabetes, cardiovascular disease (CVD), and mortality in the general population, according to a study published online Nov. 21 in Diabetologia<\/i>.<\/p>\n
Robert P. van Waateringe, from the University of Groningen in the Netherlands, and colleagues conducted a prospective analysis involving 72,880 participants from the Dutch Lifelines Cohort Study who had validated baseline skin autofluorescence values available and were not known to have diabetes or CVD.<\/p>\n
The researchers found that 1.4 percent of participants developed type 2 diabetes, 1.7 percent were diagnosed with CVD, and 1.3 percent died after a median follow-up of four years. Participants with incident type 2 diabetes and\/or CVD and those who died had elevated baseline skin autofluorescence compared with individuals who survived and remained free of type 2 diabetes and\/or CVD. Independent of traditional risk factors, such as metabolic syndrome, glucose, and hemoglobin A1c, skin autofluorescence predicted development of type 2 diabetes, CVD, and mortality.<\/p>\n
“Both previous and present findings support the clinical utility of skin autofluorescence as a first screening method for type 2 diabetes, CVD, and mortality,” the authors write. “The quick, noninvasive measurement of skin autofluorescence may even allow use in nonmedical settings or public locations such as supermarkets, pharmacies, or drug stores as a first estimate of risk.”<\/p>\n
Two authors disclosed financial ties to Diagnoptics Technologies, manufacturer of the advanced glycation endproducts (AGE) reader used in the study.<\/p>\n